Cases of AML with JAK2 and FLT3 rearrangements are also included in the current WHO classification in the category of “myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions” [24]. Here, JAK2 is linked to Increased total eosinophil count.